> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Intercept NDA for Cirrhosis
- URL: https://www.fdaweb.com/panel-to-discuss-intercept-nda-for-cirrhosis/
- Published: 2016-02-12T12:00:00.000Z
- Updated: 2026-09-15T02:35:40.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134758

*Federal Register* Notice: FDA’s Gastrointestinal Drugs Advisory Committee will meet 4/7, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss an Intercept Pharmaceuticals’ NDA for obeticholic acid oral tablets for treating primary biliary cirrhosis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Contact **Cindy Hong**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-02-12/pdf/2016-02857.pdf?ref=fdaweb.com)